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Glucocorticoids are a class of steroid hormones that are essential to life but cause seri-
ous harm in excess.The main clinical features of glucocorticoid excess are due to adverse
effects on cells and tissues that arise from a common developmental precursor – the
mesenchymal stromal cell (MSC; sometimes referred to as the mesenchymal stem cell).
Interestingly glucocorticoids appear essential for the differentiation of cells and tissues
that arise from MSCs. High levels of glucocorticoids are used in tissue engineering strate-
gies to enhance the formation of tissues such as bone, cartilage, and muscle. This article
discusses the paradox that glucocorticoids both enhance and impair MSC development
and function. It will describe how endogenous glucocorticoids are likely to be important in
these processes in vivo and will discuss the implications for therapies aimed at reducing
the damage associated with the use of therapeutic glucocorticoids.
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INTRODUCTION
Glucocorticoids are a class of steroid hormones that are essential
to life but cause serious harm in excess. The main clinical fea-
tures of glucocorticoid excess are due to adverse effects on cells
and tissues that arise from a common developmental precursor –
the mesenchymal stromal cell (MSC; sometimes referred to as the
mesenchymal stemcell). TraditionallyMSCsweremost commonly
derived from bonemarrow but have also been identiﬁed in a range
of other tissues (da Silva et al., 2006). Interestingly glucocorticoids
appear essential for the differentiation of cells and tissues that arise
from bone marrow derived MSCs. High levels of glucocorticoids
are used in tissue engineering strategies to enhance the formation
of tissues such as bone, cartilage, andmuscle. This article discusses
the paradox that glucocorticoids both enhance and impair MSC
development and function. It will describe how endogenous glu-
cocorticoids are likely to be important in these processes in vivo
and will discuss the implications for therapies aimed at reducing
the damage associated with the use of therapeutic glucocorticoids.
CUSHING’S SYNDROME
The term glucocorticoids comprises anti-inﬂammatory steroid
hormones that are produced naturally by the adrenal cortex and
related pharmaceuticals designed to treat inﬂammatory diseases.
Prolonged exposure to high levels of glucocorticoids results in
a range of clinical features referred to as Cushing’s syndrome
(Fernandez-Rodriguez et al., 2009). These features were ﬁrst noted
by Harvey Cushing in rare patients who had excess production
of cortisol (the main glucocorticoid made in the human adrenal
gland – also referred to as hydrocortisone when administered as a
pharmaceutical) as a result of an ACTH secreting pituitary tumor
(Cushing, 1932). However, after the introduction of synthetic glu-
cocorticoids in the 1950s to treat a range of inﬂammatory condi-
tions the number of patients with features of excess glucocorticoid
activity increased dramatically. The most prominent clinical fea-
tures of Cushing’s syndrome in adults are muscle wasting and
weakness, skin thinning (including easy bruising and the devel-
opment of abdominal stretch marks called striae), osteoporosis
and bone fracture, and redistribution of fat from the periphery to
the center of the body (abdomen and face; Fernandez-Rodriguez
et al., 2009). These features are thought to be due to the effects
of high levels of glucocorticoids on muscle cells, dermal ﬁbrob-
lasts, osteoblasts, and adipocytes respectively. These cell types all
share the common feature that they develop from MSCs (shown
schematically in Figure 1). The main feature of Cushing’s syn-
drome in children is growth arrest, an effect attributed to the
action of glucocorticoids on growth plate chondrocytes (Allen
et al., 1994). Chondrocytes also arise from MSCs and, as such, all
major cell types that arise fromMSCs are implicated in the changes
in body composition seen in patients with Cushing’s syndrome.
GLUCOCORTICOID-INDUCED OSTEOPOROSIS
The increased risk of fractures is frequently the most prominent
problem associated with glucocorticoid excess. The scale of this
problem is most clearly seen in patients who take oral glucocorti-
coids for the treatment of anunderlying inﬂammatorydisease (van
Staa et al., 2000). The risk of hip fracture is approximately doubled
in these individuals and the risk of hip fracture is increased up to
ﬁvefold in comparison to agematched individuals not treatedwith
oral glucocorticoids. There is also evidence that subtle states of
endogenous glucocorticoid overproduction, e.g., in the context of
adrenal adenomas that produce “mild” increases in cortisol levels
(subclinical hypercortisolemia) are associated with a substantial
increase in fracture risk, particularly at the spine (Chiodini et al.,
2009; Hardy and Cooper, 2010). The reason for the increase in
fracture risk is probably due to effects on a variety of tissues. Glu-
cocorticoid excess is associated with dramatic reductions in bone
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FIGURE 1 |The cells and tissues that arise from bone marrow derived mesenchymal stromal cells.
formation, an effect thought to be mediated primarily through
direct actions of glucocorticoids on osteoblasts (Weinstein et al.,
1998; Cooper, 2004). By contrast bone resorption is usually tran-
siently increased leading to a degree of uncoupling of formation
from resorption. The impairment of uncoupling is thought due to
an increased production of RANKL and suppression of osteopro-
tegerin expression by osteoblasts (Hofbauer et al., 1999). Both of
these actions would lead to continued stimulation of osteoclasts.
Glucocorticoids also appear to reduce the quality of matrix pro-
duced by osteoblasts and increase the rate of osteocyte apoptosis
(Weinstein et al., 1998; Lane et al., 2006). The combination of
altered matrix production and “osteonecrosis” secondary to loss
of osteocytes is likely to further reduce the resistance of bone to
fracture.
Fracture risk with oral glucocorticoids appears to increase
rapidly after starting glucocorticoids (van Staa et al., 2000). This
rapid increase in risk occurs before signiﬁcant amounts of bone
tissue are lost suggesting the possible involvement of other mech-
anisms in this effect such as an increased falls risk. An obvious
candidate for this is the effect of glucocorticoids on muscle. Glu-
cocorticoid excess causes loss of muscle mass and weakness of
muscle (myopathy) evenwhen the effects onmusclemass are taken
into account (Pereira and Freire de, 2011). This weakness appears
to be especially apparent in the central/core muscles of the body
resulting for example in difﬁculty rising from a chair. The impact
of this muscle weakness on falls risk has not been evaluated for-
mally but it is likely to be a major contributor to the increased risk
of fracture in patients treated with glucocorticoids. The changes
in fat distribution toward central fat accumulation would also be
expected to alter an individual’s center of gravity and thus also
contribute to a risk of falling. The effects of glucocorticoids on
skin (thinning and easy bruising) would also negatively impact
on the ability to withstand, and to resist damage, during a fall
(Phillips and Weightman, 2007). As such glucocorticoid-induced
osteoporosis and its consequences are likely to be dependent on
effects on several tissues arising from MSCs.
The effects of glucocorticoids on MSCs and the cells that dif-
ferentiate from MSC have been studied in vitro and in vivo. In
general the effects of glucocorticoids have been broken down into
the effects on the differentiation of MSCs to mature cells and
the effects of glucocorticoids on mature, fully differentiated cells.
The effects on MSC differentiation have primarily been explored
in vitro whereas the effects on mature cells have been studied
in vitro and in vivo. Limitations of these studies include the reliance
on MSCs from a single source (usually bone marrow) for in vitro
studies and the difﬁculty of examining fully differentiated cells in
isolation in vivo since all tissues containing these cells are likely to
contain some cells with MSC properties.
EFFECT OF GLUCOCORTICOIDS ON THE DIFFERENTIATION OF
MESENCHYMAL STROMAL CELLS
Glucocorticoids are widely used in cell culture protocols to dif-
ferentiate MSCs (e.g., those derived from bone marrow) into
mature cells (Pittenger et al., 1999; outlined in Figure 2). Glu-
cocorticoids increase the efﬁciency and yield of differentiated
osteoblasts (Haynesworth et al., 1992; Shalhoub et al., 1992),
myoblasts, adipocytes (Pittenger et al., 1999), and chondrocytes
(Kato and Gospodarowicz, 1985; Mackay et al., 1998; Derfoul
et al., 2006). The doses used in this setting is typically very high,
e.g., 1μMof dexamethasone (dexamethasone is approximately 25
times more potent than cortisol/hydrocortisone). How and why
glucocorticoids are able to induce differentiation is not known.
At a molecular level glucocorticoids bind to intracellular receptors
found within the cytoplasm (glucocorticoid receptors, GR).When
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FIGURE 2 | Overview of the effects of glucocorticoids on immature versus mature cells of the mesenchymal stromal cell lineage.These data are largely
based on clinical observations and in vitro observations using bone marrow derived mesenchymal stromal cells.
bound by GRs can migrate to the nucleus where they bind to spe-
ciﬁc sequences of DNA and inﬂuence gene transcription (Rhen
and Cidlowski, 2005). Ligand bound GR can also inﬂuence gene
transcription indirectly through interference with other signaling
pathways either in the cytoplasm or the nucleus. This interfer-
ence is particularly important for the anti-inﬂammatory effects of
glucocorticoidswhich are primarily through interferencewithNF-
κB andMAPK andAP-1 signaling pathways (Rhen and Cidlowski,
2005; Stahn and Buttgereit, 2008).
The ability of glucocorticoids to stimulate differentiation
appears to be generic to all cells that differentiate from bone mar-
row derived MSCs but the effect is more important to some cells
than others. As an illustration of this it is generally considered that
glucocorticoids are essential for the full differentiation of human
MSCs to osteoblasts with the ability to mineralize matrix and
the differentiation of chondrocytes (Eijken et al., 2005; Derfoul
et al., 2006). It is also becoming clear that even within individual
cell cultures, there may be differences in effect of glucocorticoids.
A recent study explored the mechanisms underlying glucocorti-
coid stimulation of chondrocyte differentiation and found that
selective apoptosis could be involved. Glucocorticoid treatment
tended to favor the survival and proliferation of precursors with
high potential for differentiation and proliferation whereas it
induced apoptosis of cells with more limited proliferative capacity
(Oshina et al., 2007). Whether such an effect occurs in vivo is
unknown.
EFFECT OF GLUCOCORTICOIDS ON DIFFERENTIATED CELLS
ARISING FROM MESENCHYMAL STROMAL CELLS
In contrast to the effects on immature cells glucocorticoids gen-
erally have a detrimental effect on mature cells that have differ-
entiated from MSCs (Figure 2). In osteoblasts they can induce
apoptosis and generally reduce the rate of proliferation (Wein-
stein et al., 1998; Rauch et al., 2010). At a molecular level these
effects are thought to be due to alterations in various signal-
ing pathways not least the wnt pathway (Yao et al., 2008). The
canonical wnt signaling pathway is known to be anabolic for bone
through a stimulation of bone formation. Glucocorticoids stimu-
late the expression of inhibitors of wnt signaling such asDKK1 and
secreted frizzled related proteins (sFRPs; Wang et al., 2005, 2008).
This results in reduced proliferation of osteoblasts. Glucocorti-
coids are thought to impact on muscle by increasing muscle pro-
teolysis and by inducing atrophy of mature muscle cells. Signaling
pathways affected by glucocorticoid excess include an inhibition of
local growth factor production bymyocytes and decreased expres-
sion of forkhead box class O transcription factors (FOXO) leading
to increased expression of atrophy genes such as muscle RING-
ﬁnger protein-1 (MuRf1) and atrogin-1/muscle atrophy F-box
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(MAFbx).Glucocorticoids impair the proliferationof growthplate
chondrocytes (Chrysis et al., 2003). The downstream effectors of
glucocorticoids are not known in this setting. However, in animals
this effect appears partly reversible if glucocorticoid exposure is
removed before closure of the growth plates at puberty (Schrier
et al., 2006). However, in humans glucocorticoid treatment dur-
ing childhood is associated with persistent decreases in ﬁnal adult
height (Lai et al., 2000). The mechanisms by which high levels of
cortisol alter adipocytes are unclear. Changes in adipocyte func-
tion, e.g., lipoprotein lipase (LPL) activity, preadipocyte differen-
tiation and survival, and altered adipokine secretion are all impli-
cated (Paulsen et al., 2007). In Cushing’s syndrome, LPL activity
is stimulated in retroperitoneal fat more than subcutaneous adi-
pose tissue and this could explain the central fat accumulation
(Burt et al., 2006). In human adipocytes cultured in vitro, gluco-
corticoids increase LPL mRNA expression and enzymatic activity
(Fried et al., 1993). Pharmacological doses of glucocorticoids have
been shown to stimulate lipolysis in vivo (Issekutz and Borkow,
1972;Tanaka et al., 1989).Glucocorticoids can also induce exagger-
ated adipocyte formation and hypertrophy (Rebuffe-Scrive et al.,
1988; MacDougald and Lane, 1995). Fibroblasts are heteroge-
neous with phenotypic features often related to their tissue and
site of origin (Parsonage et al., 2005). The effects of glucocorti-
coids on mature ﬁbroblasts have been most extensively studied
in skin (Schoepe et al., 2006). Dermal ﬁbroblast proliferation and
the ability to synthesize mature collagen are both substantially
reduced by high doses of glucocorticoids (features thought to
account for the clinical effects of glucocorticoids; Ponec et al.,
1977). The molecular basis for these effects is unknown but likely
to be complex given that ﬁbroblasts isolated from different tis-
sues can behave differently in response to the same treatment with
glucocorticoids.
As illustrated in the examples above it appears that there
is no single downstream mechanism by which glucocorticoids
exert their negative actions on mature cells. This suggests that
approaches to block actions of glucocorticoids downstream of the
GR are unlikely to protect all tissues against the effects of gluco-
corticoid excess. Modulation of the effects of glucocorticoids on
a broad range of cells and tissues that arise from MSCs would
be more likely by the targeting of pre-receptor mechanisms as
outlined below.
ROLE OF ENDOGENOUS GLUCOCORTICOIDS IN
MESENCHYMAL STROMAL CELL DIFFERENTIATION AND
MATURE CELL FUNCTIONING IN VIVO
Although most attention has focused on the role of therapeu-
tic glucocorticoids on MSC differentiation and function it is also
likely that normal levels of endogenous glucocorticoids have an
important role. Cortisol levels in the circulation are regulated
by the hypothalamic-pituitary–adrenal (HPA) axis. Cortisol is
secreted in a marked diurnal rhythm with high levels produced
in the hours before waking and low levels being seen through the
early part of the night. Cortisol levels are also raised dramatically
in response to a range of stressors (Cooper and Stewart, 2003).
As such glucocorticoid action at a tissue level could be regulated
by changes in the level of cortisol within the circulation or by
alteration of the sensitivity of the GR. Subtle changes in the HPA
axis with a ﬂattening out of the diurnal rhythm and a heightened
nadir level of cortisol have been reported to occur with aging (Van
Cauter et al., 1996; Hardy and Cooper, 2010). Correlations are
also seen with peak cortisol responses on ACTH stimulation test-
ing and the bone density and change in bone density over time
at various sites (Reynolds et al., 2005). These changes correlate to
some extent with bone loss and changes in body composition with
age. However, the changes seen are not consistent between stud-
ies and results often apply only to one gender or the other or are
discrepant between body regions. Further longitudinal studies are
needed to address the role of differences in cortisol levels within
the circulation in mediating changes in body composition.
Polymorphic variants of the GR which alter the sensitivity of
the GR to cortisol have been described (Manenschijn et al., 2009).
These are associated with subtle differences in body composition
suggesting that subtle differences in glucocorticoid action at a tis-
sue level could affect the development and/or health of muscle,
bone, and fat tissue. These differences however appear subtle and
only explain a small percentage of the variance in bone density
(Huizenga et al., 1998).
Further insights into the role of the GR have come from exper-
iments in which the GR has been deleted. Global deletion of the
GR is not compatible with post-natal life due to a failure of lung-
maturation. However, mice with global GR deletion appear to
form bone, muscle, and adipose tissue indicating that there is no
absolute requirement for GR signaling in the formation of these
tissues (Rauch et al., 2010). More selective disruption of the GR
has been used to dissect the role of GR signaling in various tis-
sues. Deletion of the GR in osteoblasts results in mice with mildly
reduced bone size but bone is otherwise relatively normal. Further
understanding has come about through the study of mice with a
mutation in the gene for the GR which prevents dimerization of
the GR protein (Rauch et al., 2010). Dimerization is required for
direct effects of GR on nuclear transcription but is not a require-
ment for the ability of GR to interfere with pro-inﬂammatory
signaling pathways. Interestingly these dimerization deﬁcientmice
only have a mild bone phenotype, again with slightly reduced
bone size. However the bone which is formed appears normal.
Additionally, these animals remain sensitive to the effects of ther-
apeutic glucocorticoids suggesting that the dominant pathway by
which high doses of steroids affect bone is through interference
with other signaling pathways. Overall, these data suggest that
endogenous glucocorticoids have a mild anabolic action on bone
size in vivo.
Similar GR deletion models have examined the role of endoge-
nous glucocorticoids in muscle function. Targeted deletion of GR
within muscle appears to have very little impact on muscle mass
and function under normal circumstances. However, mice with
GR deletion do not undergo muscle atrophy in response to stress-
ful stimuli (Hu et al., 2009). These observations are supported
by earlier work in which GR antagonists also provided protec-
tion against muscle atrophy in response to a range of stressors
(Aboudrar et al., 1993; Tiao et al., 1996). This suggests that, at
least under some circumstances, glucocorticoids are an essential
endogenous regulator of muscle atrophy.
Findings from models in which chondrocytes, adipocytes, or
ﬁbroblasts have been targeted for GR gene deletion are not
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currently available but these should shed light on the importance
of glucocorticoids inMSC differentiation and function in general.
More recently it has become appreciated that a major con-
tributor to glucocorticoid action at a tissue level is the activity
of glucocorticoid modifying enzymes. In particular the 11β-
hydroxysteroid dehydrogenase enzymes (11β-HSD1) have been
shown to regulate glucocorticoid action in a tissue speciﬁc fashion
(Cooper and Stewart, 2009; Raza et al., 2010). These intracellular
enzymes interconvert hormonally inactive glucocorticoids such
as cortisone and dehydrocorticosterone with their active coun-
terparts cortisol and corticosterone. They also metabolize the
most commonly used oral glucocorticoids interchanging inac-
tive prednisone with active prednisolone (Cooper et al., 2002).
There are two 11β-HSD enzymes. The 11β-HSD1 is bidirec-
tional but in vivo primarily activates glucocorticoids. 11β-HSD2
by contrast is a powerful inactivator of glucocorticoid and is
found primarily in mineralocorticoid receptor (MR) expressing
tissues. 11β-HSD2 inactivates cortisol to cortisone in these tis-
sues which prevents cortisol from binding to the MR. This leaves
aldosterone (which is not metabolized by these enzyme free to
bind the MR; Stewart et al., 1987). 11β-HSD1 has been shown
to be present in all cell types that arise from MSCs. Osteoblasts,
myoblasts, adipocytes, chondrocytes, and ﬁbroblasts all express
the enzyme (Bujalska et al., 1997; Cooper et al., 2000; Hardy
et al., 2006; Morgan et al., 2009). This suggests that these cells are
able to regulate their exposure to glucocorticoids through mod-
ulating the metabolism of glucocorticoids within the cytoplasm
before glucocorticoids have a chance to access the GR. Moreover
the expression of 11β-HSD1 appears to be very dynamic across
differentiation. In osteoblasts expression is relatively low in the
earliest precursors but increases dramatically during differentia-
tion before the activity falls back in mature cells (Eijken et al.,
2005). In adipocytes 11β-HSD1 increases with differentiation and
there is also a switch in the directionality of the enzyme favor-
ingmore glucocorticoid activation inmature adipocytes (Bujalska
et al., 1999). 11β-HSD1 also increases dramatically across mus-
cle differentiation (Morgan et al., 2009). The expression across
differentiation has not been explored in ﬁbroblasts or chondro-
cytes. In osteoblasts and adipocytes the functional importance
of 11β-HSD1 expression has been demonstrated (Bujalska et al.,
1999; Rabbitt et al., 2002). Differentiation of osteoblasts and
adipocytes in the absence of glucocorticoids is impaired. However,
this impairment can be corrected by the addition of inactive glu-
cocorticoids. Addition of inactive glucocorticoids in the presence
of an 11β-HSD1 inhibitor has no stimulatory effect on differ-
entiation conﬁrming the speciﬁcity of enzyme activity in these
effects.
Although not expressed naturally in most cells of bone mar-
row derived MSC origin the 11β-HSD2 enzyme has been used
to examine the effects of glucocorticoids on MSCs. Transgenic
overexpression of 11β-HSD2 would be expected to confer resis-
tance to glucocorticoid action. This has been demonstrated for
osteoblasts in vitro (Rabbitt et al., 2002). Selective expression of
11β-HSD2 in osteoblasts in mice in vivo resulted in subtle abnor-
malities of bone structure and density (Sher et al., 2004, 2006).
Bone density at the spine was reduced and the size of cortical
bones was lower compared to wild type mice. These results again
suggest that endogenous glucocorticoids have a mild anabolic
effect on bone. Overexpression of 11β-HSD2 in osteoblasts also
appeared to completely protect bone from the adverse effects of
high doses of synthetic glucocorticoids (O’Brien et al., 2004). This
data indicates that most of the effects of synthetic glucocorticoids
on bone density and strength aremediated directly through effects
on osteoblasts.
An interesting additional observation regarding 11β-HSD1
expression within stromal cells is the dramatic upregulation in
activity that occurs in the presence of pro-inﬂammatory cytokines
(Cooper et al., 2001; Tomlinson et al., 2001; Hardy et al., 2006,
2008; Kaur et al., 2010). The universal presence of this mechanism
in cells arising from MSCs (in contrast to the lack of effect in
lymphoid tissue or liver; Thieringer et al., 2001; Tomlinson et al.,
2001) suggests that enhanced glucocorticoid action during stress
is an important feature of the response of stromal cells to stress.
How signals relating to differentiation are integrated with signals
relating to stress and inﬂammation are currently unclear. A con-
sequence of inﬂammation induced 11β-HSD1 expression is that
cells expressing 11β-HSD1 in this setting will be disproportion-
ately affected by endogenous and exogenous glucocorticoids. This
effect could make patients with chronic inﬂammation, taking oral
glucocorticoids, particularly at risk of the development of adverse
effects in tissues arising from MSCs.
NEWLY IDENTIFIED MECHANISMS FOR MESENCHYMAL
STROMAL CELL DEVELOPMENT IN VIVO
The vast majority of previous studies have focused on bone
marrow derived MSCs as the model most likely to represent
in vivo differentiation of cells of mesenchymal origin. It was also
thought likely that these MSCs (or tissue resident cells with simi-
lar properties) were responsible for tissue repair, e.g., generation of
osteoblasts as part of bone remodeling.However, a recent studyhas
demonstrated that multipotent stem-like cells that are capable of
forming bone and cartilage can be generated in vivo from vascular
endothelial cells (Medici et al., 2010). This process of “endothe-
lial to mesenchymal transition” appears to the be the mechanism
by which abnormal bone is formed in ﬁbrodysplasia ossiﬁcans
progressiva (a condition characterized by the formation of het-
erotopic bone in muscle and soft tissues). It also appears to be
operational in fracture repair. This new insight raises questions
about the applicability to in vivo physiology of previous models
that relied on bone marrow derivedMSCs. Currently the extent to
which endothelial to mesenchymal transition occurs in vivo and
the sensitivity that these transiting cells have to glucocorticoids
is unknown. Intriguingly, mature osteoblasts have been shown to
regulate angiogenesis in bone through a glucocorticoid dependent
pathway (Weinstein et al., 2010). This suggests that osteoblasts
might be able to regulate bone formation through effects on the
supply of new endothelial precursors. Vascular endothelial cells
themselves are known to be very sensitive to glucocorticoids –
endogenous glucocorticoid levels control vascular tone through
effects on endothelial cells (Cooper and Stewart, 2003). Vascular
endothelial cells also express high levels of 11β-HSD1 (Gong et al.,
2008). This suggests that the adverse effects of high doses of gluco-
corticoids could be partly mediated through effects on the ability
of these endothelial cells to transit into mesenchymal cells.
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IMPLICATIONS FOR THERAPY
Major advances have beenmade over the last decade in the preven-
tion and protection against glucocorticoid-induced osteoporosis.
Bisphosphonates have been proven to be an effective medication
in maintaining bone density and reducing the risk of spine frac-
tures in patients treated with oral glucocorticoids (Adachi et al.,
1997, 2001; Cohen et al., 1999; Reid et al., 2009). Daily injec-
tion of the PTH analog teriparatide has been shown to be even
more efﬁcacious (Saag et al., 2007). However, the effectiveness
of these medications in reducing non-vertebral fractures is still
unclear. Additionally, these interventions do nothing to reverse
the other changes in body composition brought about by gluco-
corticoid excess. The ideal treatmentwould strengthen bonewhilst
at the same time improving muscle strength, reducing falls and
preventing the detrimental effects of glucocorticoids on skin, and
adipose tissue redistribution. Given that the downstream path-
ways associated with the adverse effects of glucocorticoids vary
considerably between tissues it is unlikely that any therapeutic
approach to tackle these post-receptor mechanisms will address
more than one component of Cushing’s syndrome. Attempts
have been made over the last 50 years to generate glucocorti-
coids that speciﬁcally target the immune system without effects
on body composition (Belvisi et al., 2001; Stahn and Buttgereit,
2008). However, despite considerable effort very little progress has
been made in this area. The recent ﬁnding that bone tissue is
affected by glucocorticoids through pathways normally associated
with suppression of inﬂammation (Rauch et al., 2010) suggests
that the previous view that the “good” effects (repression of pro-
inﬂammatory pathways) could be dissected from the “bad” effects
(stimulation of GR dimerization and direct regulation of nuclear
gene transcription–translation) is overly simplistic. Additionally,
some of the important anti-inﬂammatory effects of glucocorti-
coids appear to be through gene transactivation, e.g., the induction
of dual speciﬁcity MAPK phosphatases (Abraham et al., 2006).
With this in mind a more fruitful approach would be the
inhibition of pre-receptor glucocorticoid metabolism. Chemical
inhibitors of the 11β-HSD1 enzyme have been developed (primar-
ily to target obesity and insulin resistance in relation to endoge-
nous glucocorticoids) and are now being used in clinical trials
(Rosenstock et al., 2010). However, 11β-HSD1 appears to have
an independent role in the immune system and global inhibition
of enzyme activity could have detrimental consequences (Chap-
man et al., 2009; Cooper and Stewart, 2009). Additionally, a global
approach would have no chance of dissecting out the positive
and negative aspects of glucocorticoid action on MSCs. Currently
the best hope for selectively protecting MSCs against the adverse
effects of glucocorticoids would be to determine the molecular
mechanisms underlying the induction of 11β-HSD1 during dif-
ferentiation and during inﬂammation (Kaur et al., 2010). Selective
inhibition of the exaggerated capacity of bone, muscle, adipose
tissue and skin to generate glucocorticoids during chronic inﬂam-
mation would be particularly attractive. The success of these
approaches will of course depend on the nature of the speciﬁc
pathways involved and the feasibility of inhibiting these systemi-
cally. The clinical application of these ﬁndings will also critically
depend on the identiﬁcation and characterization of the speciﬁc
MSC subtypes involved in tissue repair in vivo.
CONCLUSION
Glucocorticoids appear to selectively impact on cells and tissues
that arise from bone marrow derived MSCs in a negative way.
This is in contrast to the positive, stimulatory effects that gluco-
corticoids have on immature cells. Therapeutic approaches to the
problems caused by glucocorticoid excess will hopefully be able
to address the adverse effects in tissues such as muscle and fat in
addition to protecting bone tissue from bone loss and fracture.
The most likely route to achieving this goal will be a focus on the
regulation of pre-receptor glucocorticoid metabolism.
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